New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
10:17 EDTJNJEarnings Preview: J&J investors will focus on catalysts, operating leverage
Johnson & Johnson (JNJ), a diversified, global healthcare conglomerate, is scheduled to report fourth quarter earnings before the open on Tuesday, January 21, with a conference call scheduled for 8:30 am ET. EXPECTATIONS: Analysts are looking for EPS of $1.20 on revenue of $17.95B, according to First Call. The consensus range for EPS is $1.19-$1.22 on revenue of $17.82B-$18.09B. LAST QUARTER: Johnson & Johnson reported Q3 adjusted EPS of $1.36 against estimates for $1.32 on revenue of $17.6B against estimates for $17.46B. At the time of its Q3 earnings release, J&J also raised its FY13 EPS view to $5.44-$5.49 from $5.40-$5.47. STREET RESEARCH: In a note to investors on January 7, RBC Capital said it expects the company's pharmaceutical franchise to continue to deliver above industry average revenue growth, and it predicts that the company will continue to have operating leverage, enabling its EPS to surpass consensus levels over the next several years. The firm raised its price target on J&J to $104 from $88. On January 10, Barclays downgraded shares of J&J to Equal Weight from Overweight. Barclays downgraded Johnson & Johnson citing limited catalysts and valuation.The firm kept its price target remains $99. PRICE ACTION: Since its last earnings report, shares of J&J are up approximately 5%. Over the last year, shares are up over 30%.
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2015
10:52 EDTJNJFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information
November 18, 2015
08:11 EDTJNJIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
08:11 EDTJNJAduro Biotech receives milestone payment from Janssen
Aduro Biotech (ADRO) announced that it has received a milestone payment from Janssen Biotech (JNJ) for Aduro's submission of an Investigational New Drug, or IND, Application to the FDA for ADU-741, a LADD immunotherapy product candidate for the treatment of prostate cancer. The IND will enable Janssen, Aduro's license partner for ADU-741, to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741 in patients with metastatic castration-resistant prostate cancer.
November 16, 2015
14:38 EDTJNJGenmab confirms FDA approval of Darzalex
Subscribe for More Information
13:09 EDTJNJFDA approves Darzalex to treat multiple myeloma
Subscribe for More Information
November 11, 2015
07:56 EDTJNJBoston Biotech Conferences to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use